12.17.14
American Medical Holdings Inc. and Bio Actives Japan Bio Inc. have collaborated to develop a new ingredient, FB3, which is a blend of three standardized botanical actives that safely and effectively inhibits absorption of excess dietary fats.
FB3 is a proprietary, international patent pending blend of Coleus forskohlii, Salacia reticulata, and Sesamum indicum — standardized for diterpene forskolin, kotanol and salacinol, and sesamin, respectively. Individually, each of these components has been shown to inhibit fatabsorption to varying degrees. This ingredient, supported by the preclinical and clinical research, is the basis of the novelty and patent application of the FB3 fusion ingredient.
A clinical study showed that FB3 led to diminished visceral fat, liver fat, body triglycerides, food cravings and caloric intake. An in vitro study found that the synergistic action of the Coleus forskohlii and Salacia reticulata in FB3 inhibited fat absorption by 20.7% — almost double the sum of the fat-blocking activity generated by each component alone.
Additionally, the study demonstrated the ingredient’s inherent safety mechanism, which occurs with the interaction of Coleus forskohlii and Sesamum indicum. This safety mechanism is intended to moderate FB3’s fat-absorption inhibition abilities, helping prevent the negative gastrointestinal and metabolic side effects that frequently occur with conventional fat blockers.
The study also showed that Coleus forskohli and Salacia reticulata work synergistically to prevent tachyphylaxis, the phenomenon of diminished response to regularly consumed ingredients for targeted action over time. This means that FB3 won’t become less effective over time or as people age.
For more information: www.bioactivesjapan.com
FB3 is a proprietary, international patent pending blend of Coleus forskohlii, Salacia reticulata, and Sesamum indicum — standardized for diterpene forskolin, kotanol and salacinol, and sesamin, respectively. Individually, each of these components has been shown to inhibit fatabsorption to varying degrees. This ingredient, supported by the preclinical and clinical research, is the basis of the novelty and patent application of the FB3 fusion ingredient.
A clinical study showed that FB3 led to diminished visceral fat, liver fat, body triglycerides, food cravings and caloric intake. An in vitro study found that the synergistic action of the Coleus forskohlii and Salacia reticulata in FB3 inhibited fat absorption by 20.7% — almost double the sum of the fat-blocking activity generated by each component alone.
Additionally, the study demonstrated the ingredient’s inherent safety mechanism, which occurs with the interaction of Coleus forskohlii and Sesamum indicum. This safety mechanism is intended to moderate FB3’s fat-absorption inhibition abilities, helping prevent the negative gastrointestinal and metabolic side effects that frequently occur with conventional fat blockers.
The study also showed that Coleus forskohli and Salacia reticulata work synergistically to prevent tachyphylaxis, the phenomenon of diminished response to regularly consumed ingredients for targeted action over time. This means that FB3 won’t become less effective over time or as people age.
For more information: www.bioactivesjapan.com
